A Dose‐finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5‐Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E‐LARC Study)

[1]  M. Berger,et al.  KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy , 2016, Annals of Surgical Oncology.

[2]  Wei Liu,et al.  Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo. , 2016, Future oncology.

[3]  R. Beart,et al.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. , 2015, Journal of the National Cancer Institute.

[4]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[5]  J. Hecht,et al.  Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. , 2015, Anticancer research.

[6]  N. Petrelli,et al.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Kerr,et al.  Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[9]  C. Dejong,et al.  Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge. , 2013, European journal of cancer.

[10]  J. Coffey,et al.  KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. , 2013, Surgical oncology.

[11]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[12]  Reiko Nishihara,et al.  Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers , 2012, Clinical Cancer Research.

[13]  D. Tait,et al.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Sunil Krishnan,et al.  Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Beißbarth,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Lawton.  Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial , 2012 .

[17]  M. Gnant,et al.  Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Yoshizawa,et al.  A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer , 2012, Angiogenesis.

[20]  M. Bracko,et al.  Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study , 2011, Radiation oncology.

[21]  Vincenzo Valentini,et al.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[24]  W. Weichert,et al.  mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. , 2011, Endocrine-related cancer.

[25]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[26]  Karin Haustermans,et al.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.

[27]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Ellis,et al.  Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[29]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[30]  C. Garrett,et al.  Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Conte,et al.  Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. , 2009, International journal of radiation oncology, biology, physics.

[32]  Y. Van Nieuwenhove,et al.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. , 2009, The Cochrane database of systematic reviews.

[33]  M. Guba,et al.  Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer , 2008, Clinical Cancer Research.

[34]  B. O'neill,et al.  Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. , 2007, The Lancet. Oncology.

[35]  P. D. Peppercorn,et al.  Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study , 2006, BMJ : British Medical Journal.

[36]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[37]  D. Hallahan,et al.  Enhanced radiation damage of tumor vasculature by mTOR inhibitors , 2005, Oncogene.

[38]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[40]  Fábio Guilherme Campos,et al.  Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results , 2004, Annals of surgery.

[41]  H. Putter,et al.  Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands , 2002, The British journal of surgery.